FDA Says GlaxoSmithKline Drug Promacta Fails to Control Bleeding

WASHINGTON - An experimental drug from GlaxoSmithKline does not significantly lower bleeding in patients with a rare blood disorder, according to the Food and Drug Administration.
MORE ON THIS TOPIC